Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Mineralys Therapeutics Inc.
Headquarters: Philadelphia, PA, United States of America
Website: https://mineralystx.com/
Year Founded: 2020
Status: Public
Industry Sector: HealthTechnology
CEO: Jon Congleton
Number Of Employees: 51
Enterprise Value: $399,337,876
PE Ratio: -3.71
Exchange/Ticker 1: NASDAQ:MLYS
Exchange/Ticker 2: N/A
Latest Market Cap: $672,780,608
See Emerging Company Profile .
BioCentury | Mar 14, 2025
Finance
Insilico, Lila draw nine-figure venture rounds: Finance Report
Plus: public companies Beam, Tarsus and Mineralys raise follow-ons
BioCentury | Mar 12, 2025
Product Development
Oral peptide win for Protagonist/J&J, Beam’s base editor POC, and more: Clinical Report
Protagonist data led to week’s biggest share price gain, while Arvinas saw biggest loss: in BioCentury’s latest Clinical Report
BioCentury | Feb 10, 2024
Finance
Public equity report: IPOs for Kyverna, Metagenomi; 4D, Sana among follow-ons
Plus PIPEs for Adverum, Autolus, Mineralys, Silence, PepGen, Sensorion, Tenaya, Jasper and others
BioCentury | Jan 6, 2024
Management Tracks
Management moves abound on eve of JPM, including new chairs for Sobi, Corteria
Plus: Zaderej to retire as AxoGen CEO and updates from AxoGen, Delfi, Illumina, Evozyne, Kiyatec, Sosei, Twist, Novocure, Be Bio, Novo Holdings, Bioluminescence and more
BioCentury | Sep 18, 2023
Product Development
Data comp: four hypertension candidates advancing in the clinic
Idorsia’s aprocitentan under review, while Mineralys and AZ prepare for Phase III trials and Alnylam runs two more Phase II studies
BioCentury | Sep 7, 2023
Deals
Idorsia’s hypertension lifeline
Swiss biotech Idorsia hopes near-term commercial opportunity for aprocitentan will spur investors to refinance the company
BioCentury | Aug 4, 2023
Finance
Biotechs that could enter the IPO queue as crossovers await liquidity
Among dozens of companies that raised crossover cash before markets turned sour, some may soon have what it takes to go public
BioCentury | Jun 23, 2023
Finance
How Apogee will test the IPO market’s appetite for preclinical risk
Backed by Fairmount Funds and Venrock and spun out of Paragon, the young start-up has an experienced CFO and is aiming for familiar targets
BioCentury | Jun 13, 2023
Finance
Turnstone to test public markets’ appetite for a biotech still waiting for clinical data
Now focused on TILs with data due in mid-2024, the company would be the fourth biotech to raise at least $20M in a NASDAQ listing this year
BioCentury | May 16, 2023
Finance
Bright spots amid the bear, IPO success story & Bio€quity ‘24 preview
Takeaways from Bio€quity Europe on the latest BioCentury This Week
Items per page:
1 - 10 of 19